Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Company Description
Gafisa is one of Brazil's largest homebuilders. It has completed more than 980 developments and constructed over 11 million square meters of housing. Gafisa serves a wide market of buyers, including the lower income housing segment through its majority ownership stake in Construtora Tenda, S.A., a separate publicly-traded company.
Third Quarter Sales Jumped 48%
On Nov 5, Gafisa reported third quarter results which saw net operating revenues rise 131% to R$877.1 million from R$378.9 million. Sales rose 48% to R$800 million.
Brazil's economy has recovered quicker from the recession than other countries.
"The gradual recovery in the economic climate and real estate market during the quarter supported the Companys strong sales and net revenue performance that positively impacted the Companys adjusted EBITDA margin of 20.4%, a 140 basis point increase when compared to the previous quarter," said Wilson Amaral, CEO.
"This improvement also reflects Tendas leadership and capacity to innovate in the affordable housing segment as it both doubled its quarterly pre-sales as compared to the prior year," he added.
Despite the credit crunch of 2009, the company grew its cash position by 4% to R$1.1 billion from R$1.05 billion as of the end of June. It continued a streak of growing its cash and cash equivalents which were just R$777.4 million at the end of third quarter of 2008.
Zacks Consensus Estimates Rise
Gafisa is bullish about 2010. It projects a strong 2010 as Brazil's is running a housing deficit of 7 million families and new household formation of 1.5 million per year.
Analysts are also optimistic about growth potential. For 2009, analysts polled by Zacks expect 234.48% earnings growth in 2009. The 2009 Zacks Consensus Estimate has jumped 32 cents to $1.94 per share in the last week.
The growth in earnings is expected to continue into 2010, as the 2010 Zacks Consensus gained 20 cents to $2.87 per share in the last 7 days. That is earnings growth of 47.68%.
Gafisa is expected to report fourth quarter results on Mar 9.
Value Fundamentals
Gafisa SA is a Zacks #1 Rank (strong buy) stock. It has a price-to-book ratio of 2.11. Gafisa also has a solid 1-year return on equity (ROE) of 14.48%, which is much higher than the industry average of 8.5%.
Gafisa also pays a dividend, with a current yield of 0.70%.
Tracey Ryniec is the Value Stock Strategist for Zacks.com. She is also the Editor in charge of the market-beating Zacks Value Trader service.
Read the full reports :
Snapshot Report on GFA